AU2013373885B2 - Oxazolidone compound, preparing method and application thereof - Google Patents

Oxazolidone compound, preparing method and application thereof

Info

Publication number
AU2013373885B2
AU2013373885B2 AU2013373885A AU2013373885A AU2013373885B2 AU 2013373885 B2 AU2013373885 B2 AU 2013373885B2 AU 2013373885 A AU2013373885 A AU 2013373885A AU 2013373885 A AU2013373885 A AU 2013373885A AU 2013373885 B2 AU2013373885 B2 AU 2013373885B2
Authority
AU
Australia
Prior art keywords
compound
present
application
relates
preparing method
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2013373885A
Other languages
English (en)
Other versions
AU2013373885A1 (en
Inventor
Shi DING
Bin Guo
Tao Xue
Yushe Yang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Institute of Materia Medica of CAS
Original Assignee
Shanghai Institute of Materia Medica of CAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Institute of Materia Medica of CAS filed Critical Shanghai Institute of Materia Medica of CAS
Publication of AU2013373885A1 publication Critical patent/AU2013373885A1/en
Application granted granted Critical
Publication of AU2013373885B2 publication Critical patent/AU2013373885B2/en
Assigned to SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES reassignment SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES Request for Assignment Assignors: SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES, ZHE JIANG JUTAI PHARMACEUTICAL CO., LTD
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epidemiology (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Catalysts (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
AU2013373885A 2013-01-18 2013-12-30 Oxazolidone compound, preparing method and application thereof Ceased AU2013373885B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201310020040.8A CN103936763B (zh) 2013-01-18 2013-01-18 噁唑烷酮类化合物及其制备方法和用途
CN201310020040.8 2013-01-18
PCT/CN2013/090833 WO2014110971A1 (zh) 2013-01-18 2013-12-30 噁唑烷酮类化合物及其制备方法和用途

Publications (2)

Publication Number Publication Date
AU2013373885A1 AU2013373885A1 (en) 2015-08-27
AU2013373885B2 true AU2013373885B2 (en) 2016-07-14

Family

ID=51184670

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013373885A Ceased AU2013373885B2 (en) 2013-01-18 2013-12-30 Oxazolidone compound, preparing method and application thereof

Country Status (8)

Country Link
US (1) US9382265B2 (enExample)
EP (1) EP2947085B1 (enExample)
JP (1) JP6242915B2 (enExample)
KR (1) KR101756570B1 (enExample)
CN (1) CN103936763B (enExample)
AU (1) AU2013373885B2 (enExample)
CA (1) CA2898550C (enExample)
WO (1) WO2014110971A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015043364A1 (zh) * 2013-09-29 2015-04-02 华北制药集团新药研究开发有限责任公司 作为凝血因子Xa抑制剂的苯并恶唑并恶嗪酮类化合物
WO2015110024A1 (en) * 2014-01-24 2015-07-30 Sunshine Lake Pharma Co., Ltd. Oxazolidinone compounds and their uses in pharmaceuticals
WO2015176677A1 (en) * 2014-05-22 2015-11-26 Sunshine Lake Pharma Co., Ltd. Crystalline forms and amorphism of oxazolidinone compound
WO2015188787A1 (en) * 2014-06-14 2015-12-17 Sunshine Lake Pharma Co., Ltd. Method for preparing oxazolidinone compound and intermediates thereof
CN105503903B (zh) * 2014-09-26 2019-04-26 华北制药集团新药研究开发有限责任公司 苯并恶唑并恶嗪酮类化合物的制备方法及其中间体和晶型
CN104610258B (zh) * 2015-02-14 2016-03-30 佛山市赛维斯医药科技有限公司 一类含酰胺和甲氧苯结构的FXa抑制剂、制备方法及其用途
CN104672236B (zh) * 2015-02-14 2016-03-30 佛山市赛维斯医药科技有限公司 一类含双酰胺基和卤代苯结构的FXa抑制剂及其用途
CN104610260B (zh) * 2015-02-14 2016-03-30 佛山市赛维斯医药科技有限公司 一类含酰胺和氮杂环结构的FXa抑制剂、制备方法及其用途
CN106478658A (zh) * 2015-08-25 2017-03-08 华北制药集团新药研究开发有限责任公司 苯并恶唑并恶嗪酮类化合物wa1-089的晶型d及其制备方法
CN106478661A (zh) * 2015-08-25 2017-03-08 华北制药集团新药研究开发有限责任公司 苯并恶唑并恶嗪酮类化合物wa1-089的晶型e及其制备方法
CN105348275A (zh) * 2015-12-10 2016-02-24 中国药科大学 噁唑烷酮类化合物及其合成方法与医药应用
CN108069983A (zh) * 2016-11-10 2018-05-25 浙江普洛得邦制药有限公司 一种噁唑烷酮类化合物的晶型及其制备方法和应用
CN108395442A (zh) * 2017-02-07 2018-08-14 浙江普洛得邦制药有限公司 一种噁唑烷酮类化合物的晶型vii及其制备方法和应用
CN108727406B (zh) 2017-03-28 2021-12-07 北京协和制药二厂 含氮杂环取代的苯并噁嗪噁唑烷酮类化合物及其制备方法和用途
CN109111465B (zh) * 2017-06-22 2021-01-12 中国科学院上海药物研究所 噻唑烷酮螺嘧啶三酮类化合物及制备方法和用途
CN108912142B (zh) * 2018-08-08 2021-06-18 延边大学 吡咯并苯并恶嗪酮类化合物及其注射剂和在抗血栓中的用途
CN114685529A (zh) * 2020-12-29 2022-07-01 中国科学院上海药物研究所 噁唑烷酮类化合物的无定形物及其制备方法和应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19805117A1 (de) * 1998-02-09 1999-08-12 Bayer Ag Neue Oxazolidinone mit azolhaltigen Tricyclen
DE10129725A1 (de) * 2001-06-20 2003-01-02 Bayer Ag Kombinationstherapie substituierter Oxazolidinone
TWI396686B (zh) * 2004-05-21 2013-05-21 Takeda Pharmaceutical 環狀醯胺衍生物、以及其製品和用法
KR20110104491A (ko) * 2008-12-19 2011-09-22 다이이찌 산쿄 가부시키가이샤 활성화 혈액 응고 제 Ｘ 인자 (ＦＸａ) 저해제
CN102260277B (zh) * 2010-05-24 2013-07-24 中国科学院上海药物研究所 新型苯并噁嗪噁唑烷酮类化合物及其制备方法和用途
CN102464658B (zh) * 2010-11-03 2014-04-16 天津药物研究院 噁唑烷酮衍生物及其制备方法和用途

Also Published As

Publication number Publication date
US20150361091A1 (en) 2015-12-17
US9382265B2 (en) 2016-07-05
EP2947085B1 (en) 2017-09-13
KR101756570B1 (ko) 2017-07-10
JP2016513076A (ja) 2016-05-12
CN103936763B (zh) 2017-10-31
WO2014110971A1 (zh) 2014-07-24
JP6242915B2 (ja) 2017-12-06
EP2947085A4 (en) 2016-06-22
CN103936763A (zh) 2014-07-23
KR20150105466A (ko) 2015-09-16
CA2898550A1 (en) 2014-07-24
EP2947085A1 (en) 2015-11-25
AU2013373885A1 (en) 2015-08-27
CA2898550C (en) 2016-08-02

Similar Documents

Publication Publication Date Title
AU2013373885B2 (en) Oxazolidone compound, preparing method and application thereof
CY1123937T1 (el) Σκευασμα ξηρης σκονης που περιλαμβανει ενα αντιχολινεργικο, ενα κορτικοστεροειδες και ενα βητα-αδρενεργικο για χορηγηση δια εισπνοης
ZA201803705B (en) 7-(thiazol-5-yl) pyrrolopyrimidine compound as tlr7 agonist
MX391180B (es) Derivado de pirazolo-heteroarilo, metodo de preparacion y uso medico del mismo
MD20140073A2 (en) New phosphate compounds, a process for their preparation and pharmaceutical compositions containing them
MD20140072A2 (ro) Noi compuşi ai pirolului, procedeu de obţinere a lor şi compoziţii farmaceutice care îi conţin
NZ705578A (en) Coated pharmaceutical composition containing regorafenib
MX2014002731A (es) Forma polimorfica de clorhidrato de pridopidina.
AU2014359194A1 (en) Lipid microcapsules preferably comprising a retinoid, and composition containing same, method for the production thereof, and use thereof in dermatology
WO2012065022A3 (en) Spiro-oxindole mdm2 antagonists
EP3072506A4 (en) Carrier for drug delivery and conjugate, composition containing same, and method for administering same
MX359288B (es) Forma iv del clorhidrato de ivabradina.
WO2015056094A3 (en) Pharmaceutical composition comprising a trpa1 antagonist and an analgesic agent
MY165888A (en) Dry powder formulation comprising a corticosteroid and a beta-adrenergic for administration by inhalation
WO2014203275A3 (en) An improved process for the preparation of apixaban and intermediates thereof
PH12015500653A1 (en) Combination drug comprising gemigliptin and metformin, and method for the preparation thereof
PH12014502407B1 (en) New alfentanil composition for the treatment of acute pain
AU2013338098A8 (en) Solid salt form of alpha-6-mPEG6-O-hydroxycodone as opioid agonists and uses thereof
PH12016500980A1 (en) Amide derivatives for gpr119 agonist
MX394413B (es) Composicion farmaceutica que contiene clomipramina y metodo de preparacion de la misma
WO2013124832A3 (en) Stabilized controlled-release pharmaceutical composition comprising gliclazide
IN2013MU02238A (enExample)
GR1008082B (el) Φαρμακευτικο σκευασμα περιεχον εναν ατυπο αντιψυχωσικο παραγοντα και μεθοδος για την παρασκευη αυτου
TN2013000202A1 (en) Spiro-oxindole mdm2 antagonists

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES

Free format text: FORMER OWNER(S): SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES; ZHE JIANG JUTAI PHARMACEUTICAL CO., LTD

Owner name: SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACAD

Free format text: FORMER OWNER(S): SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES; ZHE JIANG JUTAI PHARMACEUTICAL CO., LTD

MK14 Patent ceased section 143(a) (annual fees not paid) or expired